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Abstract
Background: Alterations in the intestinal bacterial flora are believed to be contributing factors to many chronic
inflammatory and degenerative diseases including rheumatic diseases. While microbiological fecal culture analysis is now
increasingly used, little is known about the relationship of changes in intestinal flora, dietary patterns and clinical outcome
in specific diseases. To clarify the role of microbiological culture analysis we aimed to evaluate whether in patients with
rheumatoid arthritis (RA) or fibromyalgia (FM) a Mediterranean diet or an 8-day fasting period are associated with
changes in fecal flora and whether changes in fecal flora are associated with clinical outcome.
Methods: During a two-months-period 51 consecutive patients from an Integrative Medicine hospital department with
an established diagnosis of RA (n = 16) or FM (n = 35) were included in the study. According to predefined clinical criteria
and the subjects' choice the patients received a mostly vegetarian Mediterranean diet (n = 21; mean age 50.9 +/-13.3 y)
or participated in an intermittent modified 8-day fasting therapy (n = 30; mean age 53.7 +/- 9.4 y). Quantitative aerob
and anaerob bacterial flora, stool pH and concentrations of secretory immunoglobulin A (sIgA) were analysed from stool
samples at the beginning, at the end of the 2-week hospital stay and at a 3-months follow-up. Clinical outcome was
assessed with the DAS 28 for RA patients and with a disease severity rating scale in FM patients.
Results: We found no significant changes in the fecal bacterial counts following the two dietary interventions within and
between groups, nor were significant differences found in the analysis of sIgA and stool ph. Clinical improvement at the
end of the hospital stay tended to be greater in fasting vs. non-fasting patients with RA (p = 0.09). Clinical outcome was
not related to alterations in the intestinal flora.
Conclusion: Neither Mediterranean diet nor fasting treatments affect the microbiologically assessed intestinal flora and
sIgA levels in patients with RA and FM. The impact of dietary interventions on the human intestinal flora and the role of
the fecal flora in rheumatic diseases have to be clarified with newer molecular analysis techniques. The potential benefit
of fasting treatment in RA and FM should be further tested in randomised trials.
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Background
The colon is the home for a complex mixture of microor-
ganisms that is critical for human health. The actual
number of species that may be present is controversial; it
has been estimated that >500 species coexist in the human
colon [1]. It is believed that microflora contributes to the
host's health by improving the intestinal tract's microbial
balance [2]. The idea of purported health benefits from
probiotic nutrients goes back to Elie Metchnikoff who
suggested that Bulgarian peasants lived longer because of
their yoghurt consumption which improves health by
detoxifying putrefactive substances [3]. In the meantime a
variety of potential mechanisms have been suggested to
mediate the proposed associations between microflora
and human health [4]. In the recent past interest in the
potential of improving human health through modifica-
tions of the intestinal microflora has reemerged. Various
dairy products and probiotic supplements claim such
effects. While studies are limited, it appears that overall
dietary patterns and the intake of various nutrients prima-
rily affect general patterns of the fecal microflora [5-7]. At
the same time, for subjects in feeding studies the same diet
may have very different effects on the microflora, possibly
due to differential effects of the diet on the individuals'
underlying microflora composition, and/or underlying
genetic differences [8]. Finally, experimental and observa-
tional data suggest that not only diet but also fasting and
food restriction affect the intestinal microflora [9,10].
Unfortunately, studies that attempt to associate dietary
interventions with changes in the microflora and disease
outcomes are virtually nonexistent. Nevertheless, altera-
tions in the fecal flora are increasingly believed to be con-
tributing factors to many chronic inflammatory diseases
and have attracted growing interest in the field of Comple-
mentary and Alternative Medicine [11]. First clinical evi-
dence for the health-promoting effects of probiotic drugs
or diets was derived from studies on inflammatory bowel
disease and rheumatoid arthritis (RA). In RA, the benefi-
cial effect of fasting followed by vegetarian diet on the
clinical course of the disease has been demonstrated in
randomised trials [12] and furthermore been linked to
alterations of the fecal flora, as assessed by gas-liquid
chromatography of bacterial cellular fatty acids [13]. Pre-
liminary data indicate an increase in secretory immu-
noglobulin A (sIgA) concentrations following an
extended period of fasting in patients with chronic pain
syndromes and fibromyalgia (FM) and claimed to reflect
improvements of immune function through these treat-
ments [14].
Against this background we analysed the fecal flora with
classical microbiological culture technique and evaluated
the clinical outcome in a consecutive series of patients
with RA or FM that underwent a 2-week inpatient Integra-
tive treatment period with focus on nutritional therapies.
We aimed to evaluate whether a) a Mediterranean diet or
an intermittent 8-day fasting period are associated with
changes in fecal flora, and, b) putative changes in fecal
flora are associated with clinical improvements in the two
selected diseases. Therefore, for all patients we analysed
the quantitative aerob and anaerob bacterial flora, pH and
concentrations of sIgA from stool samples at the begin-
ning, at the end of the hospital stay and at a three months
follow-up and related it to the nutritional intervention
and the clinical outcomes.
Methods
Subjects
Study subjects were inpatients from an Internal and Inte-
grative Medicine hospital department specialised in ther-
apeutic lifestyle modification and nutritional therapies in
internal diseases and rheumatic and orthopedic pain syn-
dromes. The primary established diagnosis for all partici-
pants was RA or primary FM. The study sample consisted
of consecutively admitted inpatients during two months
which regularly stayed 14 days in the clinic. All patients
were initially informed about the aim of the study and,
according to the standard clinical treatment protocols,
were offered a mostly vegetarian modified whole grain
Mediterranean diet or participated in a supervised modi-
fied fast of eight days with 2 additional pre- and 3 post fast
diet days. Patients were carefully instructed that the main
purpose of fasting therapy was not weight reduction. Con-
comitant treatments included exercise, physical therapies,
a structured program of stress reduction and some com-
plementary therapies as massage and hydrotherapy. No
supplements were given. According to a standardised pro-
tocol all patients received a similar amount of these
adjunctive therapies. Exclusion criteria to the study
included malnutrition, psychiatric disease, severe renal or
hepatic insufficiency, unstable coronary artery disease,
manifest endocrine disease, heart failure, history of cancer
and treatment with methotrexat, azathioprin, high dose
corticosteroids or antibiotics within the last 3 months.
Further exclusion criteria to fasting consisted of manifest
or prior eating disorder and severe obesity with a BMI > 40
kg/m2. Patients should not have followed any kind of spe-
cific diet in the preceding 3 months, as assessed by inter-
view and a retrospective food frequency questionnaire. 51
of 58 screened patients volunteered to participate in the
study. All patients gave their written informed consent to
the study. The study protocol was approved by the local
Ethics Committee.
Protocol and dietary interventions
The observation period started at admission (study day 1),
the dietary intervention started on the second clinical day
(study day 2) with the first of two pre-fast days for fasting
participants. At these pre-fast days fasting subjectsBMC Complementary and Alternative Medicine 2005, 5:22 http://www.biomedcentral.com/1472-6882/5/22
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received a 3350 kj (800 kcal)/day low-calorie and low-salt
diet with intake of pure cooked rice and vegetables. Sub-
jects then fasted from the evening of study day 3 to noon
at study day 11, followed by two low-calorie diet days
with stepwise reintroduction of foods. Normocaloric diet
was reached again with the evening of study day 13 for
fasting participants. During the 8-day modified fasting
period the patients received free amounts of tea (no black
or green tea), 200 cl fruit juice and small standardised
quantities of light vegetable soup with a total maximum
energy intake of 1255 kj (300 kcal)/day. Fasting started
with the oral ingestion of a laxative salt (30–40 mg Glau-
ber's salt). Patients were strongly advised to drink 2 to 3 l
of fluids daily.
Patients in the diet group received a normocaloric Medi-
terranean diet, as adapted from the Lyon Diet Heart trial
[15] and corresponding to an intake of 8372 kj (2000
kcal)/day. In brief, the diet consisted of 7 portions of fruit
and vegetables daily, the abundant intake of whole grain
bread, pasta and rice, two portions of fish/week and the
exclusive use of olive oil and canola oil for all meal prep-
arations. For all participants, fasting and non fasting-
patients, caffeine-containing or alcoholic beverages were
not allowed throughout the inpatient treatment. A dieti-
cian, trained nursing staff and a trained physician super-
vised the fasting and the control diet. All patients were
recommended to follow a Mediterranean diet with a max-
imum of one to two portions meat/week after discharge
from hospital. Throughout the inpatient period all partic-
ipants took part in a structured low-level exercise program
consisting of 30 min slow walking and non-aerobic gym-
nastics daily. Additionally, physical therapies including
hydrotherapy and massage and a validated stress reduc-
tion program (Mind/Body Program; Harvard Medical
School [16]), were delivered to all patients. No immuno-
suppressive or antibiotic treatments were allowed
throughout the study.
Clinical data and stool samples were collected at admis-
sion and at one of the last two hospital days. After 3
months patients were mailed prepaid sample tubes with a
letter asking to send the stool samples directly to the ana-
lysing laboratory.
Measurements
Bacteriological analyses
Fecal samples were collected from all subjects after defeca-
tion. The samples were immediately sent to the laboratory
(Enterosan™, Bad Bocklet-Großenbrach, Germany).
There, fecal samples were suspended and homogenised in
sterile saline. After a serial dilution in saline 0,1 ml of each
dilution was surface plated onto a series of selective and
nonselective media. The inoculated plates were incubated
at 37°C for 1 day under aerobic conditions (for enumera-
tion of Escherichia coli, other enterobacteria, enterococci
and other aerobic bacteria), respectively for 3 days under
microaerobic conditions (for enumeration of lactoba-
cilli), or for 3 days under anaerobic conditions (for enu-
meration of bifidobacteria, bacteria of bacteroides-
prevotella-porphyromonas-group and clostridia). Plates
for enumeration of yeasts and moulds were incubated at
30°C for 3 days under aerobic conditions. Following
incubation the colony-forming units were counted. Iso-
Table 1: Baseline characteristics according to diagnosis and nutritional therapy
Fasting Mediterranean Diet
FM RA FM RA
N2 1 9 1 4 7
Age, y 52.0 ± 10.0 57.7 ± 6.5 51.6 ± 13.3 49.4 ± 14.3
Female sex (n/%) 19 (90%) 9 (100%) 13 (93%) 7 (100%)
BMI, kg/m2 26.9 ± 3.7 28.8 ± 6.9 25.2 ± 3.8 23.2 ± 4.3
Disease Activity
RA (DAS 28) 62.6 ± 12.3 59.6 ± 12.3
FM (VAS) 5.1 ± 1.5 5.3 ± 1.9
Medication, n (%)
NSAIDs 10 (48) 7 (78) 7 (50) 4 (57)
Other Analgetics* 5 (24) 1 (11) 2 (14) 3 (43)
DMARDs 0 (0) 5 (56) 0 (0) 2 (29)
Corticosteroids 0 (0) 3 (33) 0 (0) 3 (43)
Nutritional intake, 
Mediterranean Diet score 
(7–35)**
22.3 ± 2.5 24.3 ± 3.5 23.2 ± 3.4 25.9 ± 3.1
Values are mean ± SD if not indicated otherwise. RA, rheumatoid arthritis; FM, fibromyalgia; VAS, Visual analogue scale; BMI = body mass index; 
NSAIDs, non-steroidal antiinflammatory drugs; DMARDs, disease-modifying antirheumatic drugs. *include opioids, amitryptiline, gabapentin. ** 
Higher scores indicating better adherence to characteristics of Mediterranean Diet.BMC Complementary and Alternative Medicine 2005, 5:22 http://www.biomedcentral.com/1472-6882/5/22
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lates were identified macroscopically and classified up to
the bacterial species by predefined morphological criteria.
Analysis of fecal secretory Immunoglobuline A (sIgA)
Measurements of sIgA-were carried out using ELISA-Kits
(Immundiagnostik, Bensheim, Germany) according to
the manufacturer's instructions. For this, feces were sus-
pended in diluent-buffer. After homogenisation and cen-
trifugation the supernatants were transferred to the
microplates, each coated with antibodies specific for sIgA.
Anti-sIgA antibody conjugated with peroxidase were used
for development. For each well the optical density was
measured at 450 nm on a microplate ELISA reader
(Dynex, Heidleberg, Germany). The results of the test
samples were calculated from the standard curve and
expressed as mg/g stool. Stool-ph was measured by stand-
ard ph-metry and quantified in 0.5 steps.
Clinical data
Diagnosis of RA and FM were each established according
to the American College in Rheumatology classification
criteria of 1987 and 1990 [17,18]. Disease activity of
patients with RA was assessed by the Rheuma Activity
Index (DAS 28) [19] using quantification of affected and
swollen joints, morning stiffness and erythrocyte sedi-
mentation rate (ESR). Activity of FM was assessed by ask-
ing the patients for the global severity of the disease-
related pain by means of a self-rating 10 cm Visual Ana-
logue Scale (VAS) with a value of 10 indicating maximum
pain and 0 indicating no pain. Patients were carefully
instructed before first self-ratings on the correct use of the
VAS. Subjects height and body weight was measured fol-
lowing a standardised protocol while patients wore light
clothing and no shoes after an overnight fast. BMI was cal-
culated as weight (kg)/ height2 (m). Anthropometrical
and clinical data were collected by trained study person-
nel. Dietary habits at baseline were evaluated by a semi-
quantitative food frequency questionnaire asking by
means of 5-point Likert scales for the intake of different
food items within the last month with a value of 0 indicat-
ing an intake of once or less in the previous month and a
value of 5 indicating an intake of at least once daily in this
period. The questionnaire asked for the following food
items: meat, sausage or meat products, fruits, vegetables
or legumes, snacks or fast-food, nuts or almonds and fish.
A Mediterranean Diet score was calculated by summaris-
ing the values for fruits, vegetables or legumes, nuts-
almonds and fish and the reversed values for meat, meat
products or sausage and snacks or fast food resulting in a
range of 5 to 35 with a value of 35 indicating most favour-
ite nutritional habits. As nearly all patients already used
olive oil or canola oil for meal preparations the intake of
olive oil was not introduced in the sum score.
Statistics
Descriptive data are presented as mean ± SD and median
with interquartile range, when applicable. For inductive
statistical analyses we took all stool parameters to their
logarithm, but left the clinical outcomes unchanged, and
fitted generalised linear models [20] to the data which
included time, treatment group, diagnostic group and
baseline values as covariates. The serial correlations were
assumed to be exponential in time. All reported tests
(group comparisons between fasters and nonfasters as
well as between patients with RA and FM) were based on
appropriate F-Tests within these models. Correlation
analysis was performed with Spearman's correlation coef-
ficient relating the courses of disease activity, stool-ph and
sIgA. All statistical computations were performed with
SAS/STAT ® statistical software version 9.1 (SAS institute,
Cary, North Carolina, USA).
Results
Baseline characteristics of all 51 patients are presented in
table 1. Female patients represented more than 90% of
patients with FM and all patients with RA. Pooling the
patients according to the received nutritional intervention
revealed a significantly higher BMI for fasting patients
(27.5 ± 4.8 kg/m2; n = 30) compared to non-fasters (mean
BMI 24.5 ± 4.0 kg/m2; n = 21). In addition, within the RA
group fasting patients were older and had more active dis-
ease compared to Mediterranean Diet patients. Further-
more, RA patients demonstrated a nonsignificant higher
baseline Mediterranean Diet score compared to FM
patients (p = 0.145). Regarding the single food items
patients with RA had a significant lower intake of sausage
and meat products compared to FM patients (p = 0.008).
The patient groups differed regarding the prescribed med-
Severity of main complaint (pain) before and at the end of the  2-week treatment period in FM patients (fasting: n = 21;  Mediterranean diet: n = 14) Figure 1
Severity of main complaint (pain) before and at the end of the 
2-week treatment period in FM patients (fasting: n = 21; 
Mediterranean diet: n = 14). P = 0.25 for between-group dif-
ference of change. Significant within-group difference of 
change for fasters (P = 0.003: t-test), but not for non-fasters 
(P = 0.240).BMC Complementary and Alternative Medicine 2005, 5:22 http://www.biomedcentral.com/1472-6882/5/22
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ication at baseline with RA patients showing higher pre-
scription rates of NSAIDs. As expected, disease modifying
antirheumatic drugs (DMARDs) and corticosteroids were
prescribed in RA patients only.
Clinical course
Adherence with the dietary regimens, as assessed by daily
interviews, was excellent. None of the patients discontin-
ued the scheduled treatment program. Mean body weight
decreased by -3.3 ± 1.4 kg in fasting patients (RA -3.5 ± 1.6
kg; FM -3.0 ± 1.3 kg) compared to -1.2 ± 0.3 kg in patients
on Mediterranean diet (RA -1.3 ± 1.2 kg; FM -1.2 ± 1.8 kg)
Fasting was well received by all patients and no relevant
adverse events occurred. The severity of disease-related
symptoms in FM patients and the disease activity in RA
patients were reduced from admission to discharge. In RA
patients the clinical improvement tended to be greater in
fasting (0.7 score points) vs. non-fasting patients (0.2
score points; group difference 0.5 points, 95%-CI: -0.1 to
1.1; p = 0.09). Fasting FM patients showed nonsignificant
greater clinical improvements than non-fasters (group dif-
ference 7.8 mm VAS, 95%-CI: -13.4 to 29.1; p = 0.25).
Within-group comparisons in both diagnostic groups
showed only for fasters a highly significant overall-treat-
ment effect (Fig. 1/2).
Stool analysis
Baseline values for all parameters showed large interindi-
vidual differences and were statistically comparable
between fasters and non-fasters and each diagnostic
group. Main data of the microbiological quantification of
the aerob fecal flora and of anaerob bacteria and candida
during the study course are presented in tables 2 and 3.
Stool-ph and concentrations of sIgA are given in table 4.
The nutritional interventions were not associated with any
significant within-group or between-group (fasters vs.
non fasters; FM vs. RA) changes from baseline to the end
of the inpatient treatment period for any of these meas-
ured parameters. Also, we found no group differences in
the composite number of anaerobic species. Three-
months-data of stool analysis were available in 43
patients (83%) and did neither reveal differences in any of
the stool parameters compared to baseline nor compared
to first follow-up. Further quantification of bacteriae and
Candida in the pooled fasting or Mediterranean diet
groups showed no relevant changes over time. Finally, in
correlation analysis the course of disease activity was not
related to sIgA concentrations or stool-ph in any of the
groups.
Discussion
It is increasingly believed that the intestinal microflora
strongly affects human health, and the quantification of
the intestinal bacterial flora quantification as an adjunc-
tive diagnostic method has gained renewed interest in the
field of Complementary and Alternative Medicine [11].
Claims of associations between specific commensal bacte-
rial species and health will have to be established in
human feeding and intervention studies, but, to date,
only a few studies have investigated the influence of diet
and fasting on the bacterial flora in patients. We hypothe-
sised that both, Mediterranean diet and fasting would dif-
ferentially alter the microflora of RA patients and that the
clinical course of these patients during the dietary inter-
vention would be connected to changes in the intestinal
microflora as assessed by cultural technique and stool
Table 2: Aerob and microaerophil (LAB) bacterial fecal flora: log. numbers of characteristic bacteria at the three timepoints in the 
different groups. No statistically significant change between time points within and between groups.
Baseline (n = 51) Discharge (n = 47) 3 Months-FU (n = 43)
Mean ± SD Median (IQR) Mean ± SD Median (IQR) Mean ± SD Median (IQR)
Escheria coli
Fasting, RA. 6.8 ± 1.6 7.6 (6.0–7.9) 7.0 ± 1.6 7.9 (6.0–8.0) 6.1 ± 1.6 6.5 (5.0–7.5)
Fasting, FM 6.7 ± 1.3 7.0 (6.0–8.0) 6.7 ± 1.4 7.0 (6.5–7.7) 6.2 ± 1.4 6.3 (5.2–7.0)
MD, RA 5.6 ± 1.9 5.3 (3.7–7.7) 5.5 ± 2.1 4.8 (3.7–7.7) 6.3 ± 1.8 6.5 (5.3.–7.8)
MD, FM 6.7 ± 1.6 7.5 (5.0–7.8) 6.4 ± 1.6 7.0 (5.0–7.6) 6.2 ± 0.8 6.0 (5.7–6.5)
Enterococcus
Fasting, RA 6.6 ± 1.0 7.0 (6.0–7.3) 6.6 ± 1.3 7.0(5.3–8.0) 6.3 ± 0.7 6.0 (6.0–6.5)
Fasting, FM 6.2 ± 1.1 6.0 (5.5–7.0) 5.6 ± 1.4 5.8(4.3–7.8) 5.9 ± 1.4 6.0 (5.2–7.2)
MD, RA 5.7 ± 0.7 5.5 (5.0–6.0) 6.0 ± 1.3 6.0 (6.0–7.0) 5.7 ± 1.5 5.8 (5.5–6.0)
MD, FM 5.9 ± 1.5 6.2 (5.0–7.0) 6.1 ± 1.5 6.1 (5.2–7.5) 5.8 ± 1.1 5.6 (5.3–6.3)
Lactobacillus (LAB)
Fasting, RA 5.8 ± 0.5 6.0 (5.5–6.3) 5.2 ± 0.8 5.5(5.3–5.6) 5.1 ± 1.0 5.3 (4.3–6.0)
Fasting, FM 5.4 ± 0.7 5.5 (5.3–6.0) 5.3 ± 0.9 5.5(4.7–6.0) 5.3 ± 1.1 5.7 (4.5–6.0)
MD, RA 4.8 ± 0.6 5.0 (4.3–5.3) 5.1 ± 1.0 5.0 (5.0–6.0) 4.2 ± 0.9 4.0 (4.0–4.5)
MD, FM 4.8 ± 1.2 5.0 (4.3–5.7) 5.7 ± 0.7 5.8 (5.5–6.0) 5.2 ± 0.9 5.3 (5.0–6.0)
FU, follow-up; IQR, interquartile range; MD, Mediterranean diet; RA, rheumatoid arthritis; FM, fibromyalgia.BMC Complementary and Alternative Medicine 2005, 5:22 http://www.biomedcentral.com/1472-6882/5/22
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sIgA concentration. However, the results of this study do
not suggest any relationship between diet, fecal culture
analysis, sIgA and disease activity in patients with RA and
FM.
Some cross-sectional studies based on cultural techniques
have indicated that the protein and fat content of the diet
as well as the nature of carbohydrates (simple sugars vs.
complex carbohydrates) do affect microflora composition
and activity [7,21]. Animal studies support the hypothesis
that the intestinal microflora can be modified by diet [8].
In contrast, food restriction has been shown in one study
to have little effect on the microflora of rats as measured
by conventional anaerobic culture [22], whereas others
have observed that food restriction and diet composition
both strongly affect the microflora composition as judged
by newer diagnostic techniques (denaturing gel gradient
electrophoresis) [23]. Generally, data from human clini-
cal studies are limited. Our results contrast to recent find-
ings from a study with 43 patients with RA, which were
randomised to an uncooked vegan diet or an ordinary
omnivorous diet [24]. After one month, the intervention
group showed a significant, diet-induced change in the
fecal flora. Furthermore, the clinical improvement was
related to the changes in fecal flora, which were assessed
by direct stool sample gas-liquid chromatography (GLC).
It has also been noted that the GLC method to study over-
all changes in fecal flora due to a vegan diet might be
superior than the classical quantitative culture of stool
sample we used [13]. Moreover, the studies' intervention
with an uncooked vegan diet rich in lactobacilli clearly
differs from the Mediterranean diet that was used in our
study. However, in a recent randomised trial on RA
patients a Mediterranean diet induced reductions in
inflammatory activity and an improvement in physical
function to a similar extent as vegan diets in the prior
studies [25]. Thus, it may be that vegan diet and Mediter-
ranean diet share nutrients that exert beneficial effects in
RA.
Of note, in a randomised trial on fasting and vegetarian
diet in RA patients significant differences in the fecal flora
were observed between samples obtained at times which
coincided with pronounced clinical improvement com-
Severity of the Disease Activity Score (DAS) before and at  the end of the 2-week treatment period in patients with RA  (fasting: n = 9; Mediterranean diet: n = 7) Figure 2
Severity of the Disease Activity Score (DAS) before and at 
the end of the 2-week treatment period in patients with RA 
(fasting: n = 9; Mediterranean diet: n = 7). P = 0.09 for 
between-group difference of change. Significant within-group 
difference of change for fasters (P = 0.007: t-test), but not for 
non-fasters (P = 0.425).
Table 3: Anaerob bacterial fecal flora and Candida log. numbers of characteristic bacteria at the three timepoints in the different 
groups. No statistically significant change between time points within and between groups.
Baseline (n = 51) Discharge (n = 47) 3 Months-FU (n = 43)
Mean ± SD Median (IQR) Mean ± SD Median (IQR) Mean ± SD Median (IQR)
Clostridia
Fasting, RA 5.8 ± 0.4 5.7 (5.7-5.7) 5.7 ± 0.1 5.7 (5.7-5.7) 5.8 ± 0.3 5.7 (5.7-5.7)
Fasting, FM 5.8 ± 0.2 5.7 (5.7-5.7) 5.8 ± 0.2 5.7 (5.7-5.7) 5.7 ± 0.1 5.7 (5.7-5.7)
MD, RA 5.7 ± 0.1 5.7 (5.7-5.7) 5.7 ± 0.2 5.7 (5.7-5.7) 5.9 ± 0.3 5.7 (5.7-5.7)
MD, FM 6.0 ± 0.6 5.8 (5.6–5.9) 5.8 ± 0.1 5.7 (5.7-5.7) 5.8 ± 0.2 5.7 (5.7-5.7)
Bidifidobacteria
Fasting, RA 7.7 ± 1.2 8.0 (7.0–8.5) 7.2 ± 1.1 7.5 (6.6–8.0) 7.7 ± 0.9 7.9 (7.5–8.0)
Fasting, FM 7.6 ± 1.2 7.7 (7.0–9.0) 7.6 ± 1.0 7.5 (7.0–8.2) 8.0 ± 0.9 8.0 (7.4–8.5)
MD, RA 7.5 ± 1.2 8.0 (6.3–8.5) 8.1 ± 0.9 8.2 (7.3–9.0) 7.9 ± 0.9 7.9 (7.3–8.0)
MD, FM 7.5 ± 1.0 7.5 (7.0–8.0) 7.4 ± 1.2 7.4 (6.5–8.2) 7.6 ± 1.4 7.5 (7.0–9.0)
Candida
Fasting, RA 2.2 ± 0.7 1.7 (1.7–2.6) 2.4 ± 0.9 2.0 (1.7–2.8) 2.4 ± 1.1 2.0 (1.7–2.6)
Fasting, FM 2.4 ± 0.9 1.7 (1.7–3.0) 2.6 ± 1.1 2.0 (1.7–2.7) 2.6 ± 1.0 2.5 (1.7–2.5)
MD, RA 2.4 ± 1.0 2.0 (1.7–3.0) 2.1 ± 0.4 1.7 (1.7–2.3) 2.2 ± 0.7 1.7 (1.7–2.6)
MD, FM 2.6 ± 0.8 2.5 (2.0–3.3) 2.4 ± 1.1 1.7 (1.7–3.2) 2.8 ± 1.0 2.8 (2.0–3.3)
FU, follow-up; IQR, interquartile range; MD, Mediterranean diet; RA, rheumatoid arthritis; FM, fibromyalgia.BMC Complementary and Alternative Medicine 2005, 5:22 http://www.biomedcentral.com/1472-6882/5/22
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pared with baseline, versus samples obtained at times of
low or no improvement [10]. Again, in this study stool
samples were analysed by GLC. Thus, apart from our dif-
fering study population with a smaller sample size of RA
patients, the conflicting result might be due to a potential
higher sensitivity of GLC compared to the classical micro-
biological cultural analysis used in the present study.
However, we also could not find any effect of the dietary
interventions on stool pH and sIgA concentrations (a
putative marker of intestinal immune function), which
supports the suggestion that Mediterranean diet and fast-
ing do not induce relevant changes in the fecal flora in the
short term. To the contrary, in an observational study on
patients with chronic pain syndromes (including FM) par-
ticipation in fasting therapy significantly increased sIgA
levels [14]. Yet, baseline sIgA concentrations in this study
were markedly lower than in our population, and the
increased concentrations at the follow-up corresponded
to baseline values in the our study. Therefore, regression
to the mean in that study may be a likely explanation for
the differing result.
In the present study RA patients tended to show better
clinical outcome with fasting than on Mediterranean Diet.
However, the interpretation of differences in clinical out-
come between the intervention groups is limited by
potential baseline differences of nutritional habits. It is
known that patients with RA frequently alter their dietary
patterns for symptom relief. In fact, In the present study
RA patients had a slightly higher nutritional score and a
reduced intake of meat compared to FM patients and the
whole population showed eating patterns with some
aspects of the Mediterranean Diet already realised before
study entry. Therefore, the clinical response and changes
in fecal flora may have been reduced in the Mediterranean
Diet group. Furthermore, due to the non-randomised
study design, fasting RA patients were older and had more
active disease compared to fasting Mediterranean Diet
patients. Thus, we cannot rule out a selection bias in the
clinical response to the two types of nutritional interven-
tions.
Another limitation relates to the short intervention time
for the Mediterranean diet. Indeed, the clinical benefit of
a Mediterranean diet in patients with RA was more evi-
dent after 12 than after three or six weeks of intervention
time [25]. In contrast, change to an uncooked vegan diet
and the return to a Western diet induced alterations in the
fecal flora within one to two weeks [13]. Clearly, future
studies on the association between Mediterranean diet
and intestinal microflora should evaluate longer study
periods as minor changes could accumulate over time.
A principal limitation of the present study relates to the
small sample size. This implies that no definite conclu-
sions should be drawn from our data. However, the com-
plete absence of effects of the interventions on the
bacterial flora makes it unlikely that a larger sample size
would have yielded different results. Other factors, as
medication, may also have influenced the bacterial flora.
Yet, neither probiotics or antibiotics were given, and,
within the diagnostic groups there were no other relevant
differences of prescribed medication between fasters and
patients on Mediterranean Diet. Another limitation that
applies to all research testing fecal samples to determine
bacterial flora is the influence of the fecal water concentra-
tion. This factor may not only vary from individual to
individual, but within individuals within the same day.
However, drying the stool would not be possible without
compromising the presence of certain bacteria.
It may be further argued whether microbiologic analysis
of the fecal flora with its limitations in diagnostic accuracy
Table 4: Stool pH and secretory immunoglobulin A (sIgA) stool concentrations according to group assignment in the study course: No 
statistically significant change between different time points within and between groups.
Baseline (n = 51) Discharge (n = 47) 3 Months-FU (n = 43)
Mean ± SD Median (IQR) Mean ± SD Median (IQR) Mean ± SD Median (IQR)
PH
Fasting, RA 7.2 ± 0.8 7.5 (7.0–8.0) 7.5 ± 0.5 7.5 (7.0–7.5) 6.8 ± 0.5 7.0 (6.5–7.0)
Fasting, FM 7.2 ± 0.9 7.0 (7.0–8.0) 7.2 ± 0.8 7.5 (6.5–8.0) 6.8 ± 0.9 6.5 (6.5–7.5)
MD, RA 7.4 ± 0.8 7.0 (6.5–8.0) 7.5 ± 0.5 7.5 (7.0–8.0) 6.9 ± 0.7 7.0 (6.5–7.5)
MD, FM 7.4 ± 0.7 7.5 (6.5–8.0) 7.3 ± 0.8 7.5 (6.5–8.0) 7.2 ± 0.7 7.5 (6.5–7.5)
IgA
Fasting, RA 1.3 ± 1.2 1.2 (0.4–1.4) 1.0 ± 0.7 0.9 (0.6–1.1) 1.8 ± 2.8 0.5 (0.4–1.4)
Fasting, FM 1.1 ± 1.0 0.7 (0.4–1.5) 1.1 ± 0.1 0.7 (0.4–1.7) 1.1 ± 0.9 1.0 (0.3–1.8)
MD, RA 1.3 ± 1.7 0.6 (0.2–2.1) 0.6 ± 0.7 0.4 (0.3–0.6) 0.8 ± 0.5 0.6 (0.5–1.0)
MD, FM 1.0 ± 1.2 0.5 (0.4–0.8) 0.7 ± 0.9 0.5 (0.3–0.6) 0.8 ± 1.1 0.4 (0.3–0.7)
FU, follow-up; IQR, interquartile range; MD, Mediterranean diet; RA, rheumatoid arthritis; FM, fibromyalgia.BMC Complementary and Alternative Medicine 2005, 5:22 http://www.biomedcentral.com/1472-6882/5/22
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is the appropriate method to assess treatment effects.
However, culture is the classical approach for the identifi-
cation and quantification of bacteria. Most of the data
available on the gut bacteria have been generated by culti-
vation and enumeration [26]. Still, this approach is lim-
ited in scope, as a majority of the bacterial species present
in feces are not culturable using standard microbiologic
techniques. Yet, we believe that the lack of effect of the
interventions on sIgA in our study further points to the
suggestion that the intestinal microflora is not connected
to the dietary treatments and clinical outcome in the
selected patient groups. There are now refined develop-
ments with molecular analysis tools including the availa-
bility of the completed genome sequences [26]. Given
their expense, these newer molecular techniques await
their broader implementation in clinical research. Clearly,
the future utilisation of molecular microflora analysis
tools can help to clarify a potential interplay between diet
and human microbiota.
Finally, it is important to note that labelling nonpatho-
genic commensal bacteria as either beneficial or detrimen-
tal remains highly speculative. Yet, as we did not found
any alterations in the fecal flora of our patients, this issue
remains negligible for the interpretation of our results.
Conclusion
In recent years, the interest of using intestinal flora analy-
sis for clinical purposes has increased. In rheumatic dis-
eases a role for diet-induced alterations in fecal flora has
been suggested. The present study revealed that fasting or
Mediterranean diet do not affect the bacterial counts and
sIgA levels in the intestinal tract in patients with RA and
FM in a two-week period and that the clinical outcome of
dietary intervention is not related to changes in intestinal
flora. Given the numerous claims of associations between
the intestinal flora and human health future studies that
include newer molecular techniques should clarify the
impact of intestinal flora on clinical outcome and the pos-
sible modification through diet. Using the classical micro-
biological technique there seems to be no role for fecal
flora analysis in the clinical approach to rheumatic dis-
eases.
Our data further suggest that the efficacy of fasting in the
treatment of FM should be addressed in randomised tri-
als, given that the clinical course in both, patients with FM
and RA, appeared to be beneficially affected by fasting. For
RA the benefit was more apparent, a result which is con-
sistent with data from previous randomised trials which
demonstrated fasting to be an efficacious treatment in RA
[12,27]. Our data indicate that FM patients might also
benefit from fasting treatment. Specific effects of fasting
on neuroendocrine regulation, central serotonin availa-
bility and quality of sleep have been previously reported
[28-30] and point to potential mechanisms of symptom-
relief in chronic pain syndromes.
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